Soluble guanylyl cyclase expression is reduced in acute lung injury Source: Eur Respir J 2006; 28: Suppl. 50, 398s Year: 2006
Resistive breathing reduces soluble guanylyl cyclase expression Source: Annual Congress 2009 - Cell biology of lung disease Year: 2009
The stimulator of soluble guanylate cyclase riociguat protects against bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
Intrapulmonary renin angiotensin activation in antigen-induced airway hyperresponsiveness Source: Eur Respir J 2007; 30: Suppl. 51, 134s Year: 2007
A fully dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a murine model of asthma Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010
The role of isoprenylation in lipopolysaccharide (LPS)-induced human airway hyperresponsiveness Source: Annual Congress 2010 - Models of airways disease Year: 2010
Inhibition of the alternative complement pathway abolishes the development of airway hyperresponsiveness (AHR) and inflammation Source: Eur Respir J 2004; 24: Suppl. 48, 348s Year: 2004
Effect of neutrophil elastase inhibitor on airway inflammation and airway hyperresponsiveness in a murine model of asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
Role of Rho kinase isoforms in murine allergic airway responses Source: Eur Respir J 2011; 38: 841-850 Year: 2011
The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
A dual role of IL-6 signalling and STAT-3 activation on airway inflammation versus airway hyperresponsiveness in a murine model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 568s Year: 2002
The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007
Activated protein C inhibits bronchial inflammation and hyperresponsiveness in a mouse model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
Inhibitors of NADPH-oxidase or nitric oxide synthase prevent airway hyperresponsiveness but not allergic inflammation in mice Source: Eur Respir J 2001; 18: Suppl. 33, 265s Year: 2001
The different effect of NO-synthase inhibitors in allergen and toluene-induced airway hyperreactivity Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
The PAR2 -activating peptide SLIGRL inhibits airway hyper-responsiveness and eosinophilia in an acute murine model of allergic asthma Source: Annual Congress 2004 - Animal models of asthma and chronic bronchitis and their relevance in pulmonary pharmacology Year: 2004
Regulated lung-specific overexpression of nitric oxide induces airway hyperresponsiveness in mice Source: Eur Respir J 2002; 20: Suppl. 38, 568s Year: 2002
Allergen-induced BDNF expression and neuronal remodeling contributes to airway hyperresponsiveness Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Montelukast inhibits bronchoconstriction and gas exchange defects induced by leukotriene D4 challenge in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
Methacholine airway hyperresponsiveness is associated with fraction of nitric oxide irrespective of asthma Source: Annual Congress 2012 - Mechanisms and risk of childhood asthma and allergy Year: 2012